Orchard Therapeutics PLC
Marc became chief executive officer of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. Marc previously served as executive director and chief financial officer of AstraZeneca since November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel, and GSK, has given him extensive industry experience. Marc joined AstraZeneca in 2013, serving as executive vice president, global product and portfolio strategy from June to October 2013. Prior to that, he served as global head of rare diseases at GSK and (concurrently) chairman, GSK Japan.
Marc earned his MBA from the Hautes Etudes Commerciales and a Bachelor of Law degree from Paris University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.